Abbott

Q3 2019
FINANCIAL RESULTS

LIFE-CHANGING TECH DELIVERS EXCEPTIONAL GROWTH

SALES WORLDWIDE

$8.1 billion

+7.6%[1] on organic basis*

STRONG PERFORMANCE ACROSS ABBOTT[2]
SALES ON ORGANIC BASIS*

+10.6% MEDICAL DEVICES

+6.6% DIAGNOSTICS

+3.8% NUTRITION

+7.9% ESTABLISHED PHARMACEUTICALS

NARROWED FULL-YEAR 2019 EPS GUIDANCE[3]

$3.23 TO $3.25

Adjusted diluted EPS midpoint reflects double-digit growth

KEY PRODUCTS DRIVE EXCEPTIONAL PERFORMANCE

FREESTYLE LIBRE

SALES UP **68%**

ON ORGANIC BASIS[4]

- FreeStyle® Libre, the first sensor-based glucose monitoring system listed in any Canadian provincial health plan, gained public reimbursement in Ontario and Quebec
- Abbott enters new collaborations with Sanofi, Omada Health and Tandem Diabetes Care to provide people with diabetes a connected device experience

MITRACLIP

SALES UP **32%**

ON ORGANIC BASIS[5]



- COAPT™ Trial data show MitraClip® is cost effective, increases life expectancy and improves quality of life
- MitraClip® G4 — Now approved in the U.S., our next-generation device for mitral valve repair includes new clip sizes and an enhanced leaflet grasping feature

CORE LABORATORY DIAGNOSTICS

SALES UP **11%**

ON ORGANIC BASIS[6]

- Strong adoption of Alinity family of advanced diagnostic testing technologies due to increased speed and efficiency in laboratories
- Alinity® - S — Our most advanced system for screening blood and plasma is now approved in the U.S. to help keep the blood supply safe

* Organic sales growth excludes the prior year first-, second- and third-quarter results for a non-core business within U.S. Adult Nutrition, which was discontinued during the third-quarter 2018; and excludes the impact of foreign exchange. For full financial data and reconciliation of non-GAAP measures, please see our press release dated October 16, 2019, available at www.abbottinvestor.com.

1. On a GAAP basis, Abbott sales increased 5.5%. **2.** On a GAAP basis, Medical Devices sales increased 8.9%; Diagnostics sales increased 4.7%; Nutrition sales increased 2.0%; and Established Pharmaceuticals sales increased 4.4%. **3.** Adjusted diluted EPS excludes specified items. On a GAAP basis, full-year guidance is $2.06 to $2.08. **4.** On a GAAP basis, FreeStyle Libre sales increased 63.1%. **5.** On a GAAP basis, MitraClip sales increased 30.4%. **6.** On a GAAP basis, Core Laboratory Diagnostics sales increased 8.3%.